Stifel on Thursday initiated coverage on Immunic Inc. IMUX, a late-stage biotechnology company developing oral therapies for ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ...
Bionxt has completed manufacturing of a batch of BNT23001, its under-the-tongue formulation of cladribine, for use in MS ...
FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its ...
The multiple sclerosis market presents opportunities in developing innovative therapies, leveraging collaborations, and advancing clinical trials. Key players focus on new drug mechanisms and ...
On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t be completed by the end of the year and a trial for a different form of MS ...
A woman whose multiple sclerosis masked the symptoms of an incurable blood cancer has outlived her prognosis of three to ...
Sanofi’s experimental multiple sclerosis drug tolebrutinib has encountered two major setbacks: a delayed regulatory decision in the U.S. and a failed late-stage clinical trial. The French drugmaker ...
The National Institute for Health and Care Excellence (NICE) has recommended natalizumab for treating adults with highly active relapsing-remitting multiple sclerosis (RRMS) whose disease has ...
The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results